<DOC>
	<DOCNO>NCT02449473</DOCNO>
	<brief_summary>A Multicentre , Randomized , Double-blind , Parallel Group , Placebo Controlled , 12-Week , Phase 2 Study Evaluate Effect Tralokinumab Airway Inflammation Adults Asthma Inadequately Controlled Inhaled Corticosteroid .</brief_summary>
	<brief_title>Study Evaluate Efficacy &amp; Safety Tralokinumab Subjects With Asthma Inadequately Controlled Corticosteroids</brief_title>
	<detailed_description>This multicentre , randomize , double-blind , parallel group , placebo-controlled , phase 2 study design evaluate effect 300 mg dose tralokinumab administer subcutaneously every 2 week airway inflammation adult asthma inadequately control inhaled corticosteroid ( ICS ) without controller . Approximately 80 subject randomize . Subjects receive tralokinumab , placebo , administer via subcutaneous injection study site , 12 week treatment period .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Age 18 75 year 2 . Documented physiciandiagnosed asthma least 12 month prior enrolment ( v1 ) 3 . Documented treatment asthma controller regimen require treatment ICS ( minimum dose ≥ 250 ug fluticasone propionate via dry powder inhaler equivalent total daily dose ) alone combination ≥ 6 month take stable dose least 1 month prior enrolment ( v1 ) 4 . Additional maintenance asthma controller medication must give stable dose least 1 month prior v1 . 5 . At enrolment ( v1 ) subject must predict normal value ( PNV ) prebronchodilator ( BD ) FEV1 &gt; 50 % 1L . 6 . PostBD reversibility FEV1 ≥12 % ≥200 mL enrolment ( v1 ) . 1 . History interstitial lung disease , chronic obstructive pulmonary disease ( COPD ) , clinically significant lung disease asthma . 2 . History anaphylaxis follow biologic therapy . 3 . Hepatitis B , C HIV 4 . Pregnant breastfeed 5 . History cancer 6 . Current tobacco smoke history tobacco smoke &gt; 10 packyears . 7 . Previous receipt tralokinumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Reactive Airways</keyword>
	<keyword>Respiratory Tract Disease</keyword>
	<keyword>Obstructive Tract Disease</keyword>
	<keyword>Lung Diseases</keyword>
</DOC>